Heteroaryl Syk inhibitors

US9914735B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Georg Dahmann · Biberach an der Riß, DE
• Matthias Hoffmann · Mittelbiberach, DE
• Jasna Klicic · Biberach an der Riß, DE
• David James LAMB · Mittelbiberach, DE
• Clive McCarthy · Woodstock, GB
• Spencer Charles R. Napier · Abingdon, GB
• Karen PARRISH · Abingdon, GB
• John Scott · Abingdon, GB
• Jennifer L. Swantek FITZGERALD · Ridgefield, US
• Edward Walker · Biggenden, AU

Key dates

• Filing date: Mar 12, 2015
• Grant date: Mar 13, 2018
• Expiry date: Mar 12, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.